Across TCGA pan-cancer cohorts, CD300LF RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of CD300LF’s most consistent transcriptional readouts.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CD300LF RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CD300LF is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.
KIRC, HNSC, and THCA are the cancer types where CD300LF tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CD300LF RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.